211 related articles for article (PubMed ID: 32948918)
21. [Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function].
Helke C; May M; Hoschke B
Aktuelle Urol; 2006 Sep; 37(5):363-8. PubMed ID: 17004181
[TBL] [Abstract][Full Text] [Related]
22. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
24. Iohexol plasma clearance for measuring glomerular filtration rate: effect of different ways to calculate the area under the curve.
Pottel H; Schaeffner E; Ebert N; van der Giet M; Delanaye P
BMC Nephrol; 2021 May; 22(1):166. PubMed ID: 33952185
[TBL] [Abstract][Full Text] [Related]
25. Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene.
Calvert AH; Ghokul S; Al-Azraqi A; Wright J; Lind M; Bailey N; Highley M; Siddiqui N; Lunec J; Sinha D; Boddy A; Roberts T; Fenwick J
Semin Oncol; 1999 Feb; 26(1 Suppl 2):90-4. PubMed ID: 10190788
[TBL] [Abstract][Full Text] [Related]
26. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
27. Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity.
Bretagne M; Jouinot A; Durand JP; Huillard O; Boudou Rouquette P; Tlemsani C; Arrondeau J; Sarfati G; Goldwasser F; Alexandre J
Cancer Chemother Pharmacol; 2017 Jul; 80(1):45-53. PubMed ID: 28508095
[TBL] [Abstract][Full Text] [Related]
28. Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine.
Wang H; Li M; Rinehart JJ; Zhang R
Cancer Chemother Pharmacol; 2004 Jun; 53(6):459-67. PubMed ID: 14752578
[TBL] [Abstract][Full Text] [Related]
29. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
30. Plasma clearance of iodine contrast media as a measure of glomerular filtration rate in critically ill patients.
Erley CM; Bader BD; Berger ED; Vochazer A; Jorzik JJ; Dietz K; Risler T
Crit Care Med; 2001 Aug; 29(8):1544-50. PubMed ID: 11505124
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
Duong JK; Veal GJ; Nath CE; Shaw PJ; Errington J; Ladenstein R; Boddy AV
Br J Clin Pharmacol; 2019 Jan; 85(1):136-146. PubMed ID: 30261554
[TBL] [Abstract][Full Text] [Related]
32. Carboplatin dosing for adult Japanese patients.
Ando Y; Shimokata T; Yasuda Y; Hasegawa Y
Nagoya J Med Sci; 2014 Feb; 76(1-2):1-9. PubMed ID: 25129986
[TBL] [Abstract][Full Text] [Related]
33. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
Konecny G; Untch M; Slamon D; Beryt M; Kahlert S; Felber M; Langer E; Lude S; Hepp H; Pegram M
Breast Cancer Res Treat; 2001 Jun; 67(3):223-33. PubMed ID: 11561768
[TBL] [Abstract][Full Text] [Related]
34. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
[TBL] [Abstract][Full Text] [Related]
35. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Patnaik A; Warner E; Michael M; Egorin MJ; Moore MJ; Siu LL; Fracasso PM; Rivkin S; Kerr I; Litchman M; Oza AM
J Clin Oncol; 2000 Nov; 18(21):3677-89. PubMed ID: 11054441
[TBL] [Abstract][Full Text] [Related]
36. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.
Soo RA; Wang LZ; Tham LS; Yong WP; Boyer M; Lim HL; Lee HS; Millward M; Liang S; Beale P; Lee SC; Goh BC
Ann Oncol; 2006 Jul; 17(7):1128-33. PubMed ID: 16670205
[TBL] [Abstract][Full Text] [Related]
37. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
38. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
39. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
Lockhart AC; Bauer TM; Aggarwal C; Lee CB; Harvey RD; Cohen RB; Sedarati F; Nip TK; Faessel H; Dash AB; Dezube BJ; Faller DV; Dowlati A
Invest New Drugs; 2019 Feb; 37(1):87-97. PubMed ID: 29781056
[TBL] [Abstract][Full Text] [Related]
40. The renal safety and efficacy of combined gemcitabine plus cisplatin and gemcitabine plus carboplatin chemotherapy in Chinese patients with a solitary kidney after nephroureterectomy.
Sun P; Xue C; Li LR; Shao C; An X; Thomas R; Yang W; Deng YF; Jiang WQ; Shi YX
Cancer Chemother Pharmacol; 2017 Jul; 80(1):37-44. PubMed ID: 28534209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
